What Is the Life Expectancy for Plasma Cell Leukemia?

Life expectancy for plasma cell leukemia depends heavily on which type a person has, when they were diagnosed, and what treatments they receive, but the numbers are sobering either way. For primary plasma cell leukemia (pPCL), which arises on its own rather than evolving from an existing cancer, recent multicenter data show roughly three-quarters of patients surviving one year and just under half surviving three years with modern drug regimens.¹ For secondary plasma cell leukemia (sPCL), which develops when multiple myeloma transforms into a more aggressive form, the median survival is only around three months.² These figures represent meaningful improvement over past decades, but plasma cell leukemia remains one of the most aggressive blood cancers.

Primary Versus Secondary Makes All the Difference

The single most important factor in predicting how long someone with plasma cell leukemia will survive is whether their disease is primary or secondary. Primary PCL shows up in people who have never been diagnosed with multiple myeloma before. Secondary PCL develops in patients who already have myeloma that has progressed or relapsed into a leukemic phase, meaning large numbers of malignant plasma cells spill into the bloodstream.

A large US cohort study found a median overall survival of about 37 months for primary PCL compared to just 3.2 months for secondary PCL.² That gap is enormous. An earlier study from Japan reported similar patterns, with primary PCL patients surviving a median of about 22 months and secondary PCL patients only 1.3 months.³ The difference in specific numbers across studies reflects how rare this disease is and how much outcomes vary by treatment era and regimen, but the direction is consistent: secondary PCL carries a far worse prognosis because the cancer has already been through prior treatments and developed resistance.

Why the Definition Recently Changed

Until recently, PCL was defined by having at least 20 percent circulating plasma cells in the blood or an absolute count above a certain threshold. In 2021, the International Myeloma Working Group lowered that cutoff to 5 percent or more circulating plasma cells in a patient otherwise diagnosed with symptomatic multiple myeloma.⁴ This matters for life expectancy discussions because the revised criteria capture patients earlier in disease progression. Some patients who would previously have been classified as having aggressive myeloma are now diagnosed with PCL, which can shift published survival statistics. A recent review confirmed this revised threshold of 5 percent or more circulating plasma cells for pPCL diagnosis.⁵

When you see older studies reporting median survival of only a few months, keep in mind those were using the stricter 20 percent cutoff, meaning only patients with very advanced circulating disease were included. Newer studies using the 5 percent threshold may include patients with somewhat less extreme presentations, which could partly explain some of the improvement in reported survival numbers beyond just better drugs.

How Much Survival Has Improved Over Time

A population-level analysis of 445 patients from the US national cancer database tracked survival trends across several decades. Patients diagnosed between 1973 and 1995 had a median survival of just 5 months. That number barely budged through 2005, hovering between 4 and 6 months. Then, for patients diagnosed between 2006 and 2009, median survival jumped to 12 months.⁶ That shift coincided with the introduction of newer drug classes and their widespread use as first-line treatment.

More recent data from patients treated with contemporary regimens paint a more encouraging picture for primary PCL specifically. In a multicenter study of pPCL patients treated with newer agents, the one-year survival rate was about 75 percent, two-year survival about 58 percent, and three-year survival close to 48 percent.¹ Those numbers represent a dramatic improvement over the single-digit-month median survivals that defined this disease for decades. Still, roughly half of patients do not make it to three years, which underscores how aggressive primary PCL remains even with the best available treatments.

Treatments That Have Changed the Outlook

The survival gains in pPCL are largely attributable to drug combinations borrowed and adapted from the treatment of multiple myeloma. The most significant advance has been the use of bortezomib, a proteasome inhibitor, as part of initial therapy. Retrospective studies from Italy showed that using bortezomib-containing regimens upfront improved both the quality of responses and overall survival compared to older chemotherapy.⁷ Studies report overall response rates up to 79 percent with bortezomib-based regimens, and the drug appears to partially counteract the bad prognosis associated with certain genetic abnormalities that are common in pPCL.⁸

A Greek study with one of the longest reported follow-up periods in this disease found that patients treated with bortezomib-based regimens had a median overall survival of 13 months, compared to just 2 months with conventional chemotherapy.⁹ Most current treatment protocols combine bortezomib with an immunomodulatory drug like lenalidomide, and the same Greek group later showed that these triple combinations or daratumumab-based four-drug regimens pushed survival even further. Patients on VRd (bortezomib, lenalidomide, dexamethasone) or daratumumab-based quadruplets had a three-year survival rate of 70 percent, compared to 32 percent for those on older bortezomib-based combinations.¹⁰

Adding daratumumab, an antibody that targets a protein called CD38 on the surface of plasma cells, has shown an overall response rate of about 68 percent in PCL patients.¹¹ These regimens now represent the standard approach for eligible patients.

Stem Cell Transplantation

For patients healthy enough to undergo it, autologous stem cell transplantation (using the patient’s own cells) remains an important part of treatment. In the largest reported study at the time, patients with pPCL who received an autologous transplant had a median overall survival of about 26 months, though this was still substantially shorter than the 62 months seen in myeloma patients undergoing the same procedure.¹² A systematic review and meta-analysis found the pooled three-year overall survival after autologous transplant was about 51 percent, though the relapse rate was high at around 68 percent.¹³

In the US cohort study, pPCL patients who received a transplant had a median survival of nearly 50 months, compared to about 12.5 months without transplant. Even for secondary PCL, the small number of patients who received transplantation survived a median of 16 months versus 3.4 months without it.² The challenge is that many PCL patients are too sick at diagnosis to qualify for transplant, and even among those who do, the disease tends to come back relatively quickly.

Allogeneic transplantation, using donor cells, offers the theoretical advantage of a graft-versus-tumor effect, but studies have not shown a clear survival benefit over autologous transplant in PCL. One study found median overall survival of 40 months after allogeneic versus 19 months after autologous transplant, but the difference was not statistically significant, and relapse remained the primary cause of death regardless of transplant type.¹⁴

Genetic Factors and What Drives the Aggression

Plasma cell leukemia tends to carry a particularly unfavorable set of genetic abnormalities. One of the most striking findings is how commonly the tumor suppressor gene TP53 is knocked out. Research found TP53 inactivation, either through mutation or deletion of the chromosome region where it sits, in about 56 percent of primary PCL patients and 83 percent of secondary PCL patients.¹⁵ Loss of TP53 function is associated with treatment resistance across many cancers, and its near-universal presence in PCL helps explain why the disease is so hard to control.

Beyond TP53, pPCL patients tend to present with markers of aggressive disease: low hemoglobin, high levels of beta-2-microglobulin and LDH (a marker of cell turnover), and low albumin.¹⁶ These lab values help doctors gauge prognosis at diagnosis and are factored into treatment decisions. The Greek multicenter study identified deletion of chromosome 17p (which contains TP53) and low platelet counts as independent predictors of shorter survival alongside choice of treatment regimen.¹⁰

Early Death Remains a Real Risk

One of the harsh realities of plasma cell leukemia is how many patients die within weeks of diagnosis, before treatments have a chance to work. A study examining early mortality in newly diagnosed myeloma-spectrum diseases found that a diagnosis of primary PCL was one of the strongest independent risk factors for dying early.¹⁷ Other factors that increased the risk of early death included low albumin, high calcium levels, and elevated LDH. Infections, especially pneumonia, were the leading cause of early death, followed by kidney failure and heart failure. Patients with PCL are often profoundly immunocompromised at diagnosis, and the aggressive tumor burden can overwhelm organ function before induction therapy has time to take effect.

This is an important caveat when reading survival statistics. Median survival figures include patients who died in the first weeks alongside patients who responded well and lived for years. For patients who survive the initial treatment period and achieve a good response, the personal outlook can be considerably better than the population-level median suggests.

Emerging Therapies on the Horizon

For patients whose disease relapses after standard treatments, there is growing interest in two newer classes of therapy. Venetoclax, a drug that targets a protein called BCL-2, has shown promise in PCL patients who carry a specific genetic rearrangement known as translocation t(11;14). A literature review of case reports found that most patients treated with venetoclax-based combinations achieved deep responses, with the treatment generally well tolerated.¹⁸ The limitation is that this genetic rearrangement is present in only a subset of patients, so venetoclax is not broadly applicable.

CAR-T cell therapy, which engineers a patient’s own immune cells to recognize and attack cancer cells, has generated particular excitement. A retrospective study of 12 patients treated with BCMA-targeted CAR-T cells reported an overall response rate of 75 percent, with a median overall survival of about 15.5 months and a one-year survival rate of roughly 56 percent.¹⁹ Individual case reports have documented complete responses lasting months in patients with secondary PCL who had exhausted other options.²⁰ These are small numbers and early data, but for a disease with few effective salvage options, the results are encouraging enough that CAR-T is increasingly being incorporated into treatment strategies for relapsed PCL.

When the Disease Hides in the Brain

One of the more feared complications of PCL is central nervous system involvement. Most treatments for myeloma and PCL do not cross the blood-brain barrier effectively, which means the brain and spinal cord can act as a sanctuary site where cancer cells survive even while the disease is controlled elsewhere in the body. Case reports have documented patients achieving complete systemic remission, with all their blood and bone marrow tests looking clean, while malignant plasma cells were quietly growing in the lining of the brain.²¹

Central nervous system involvement in PCL is uncommon, but when it occurs, outcomes are very poor. There is growing recognition that patients with certain high-risk features, particularly those with disease that has spread beyond the bone marrow (extramedullary disease), should be evaluated for CNS involvement. Effective treatment of CNS disease requires drugs or therapies that can reach the brain, and the options are limited. Intrathecal chemotherapy (injected directly into the spinal fluid) and whole-brain radiation have been used, but responses tend to be brief. Whether newer agents like CAR-T cells, which can sometimes cross into the central nervous system, might offer a better chance in these patients is an active area of investigation.

Disparities in Hospitalization and Access

Given that aggressive cancers often expose healthcare inequities, researchers have looked at whether race, income, or geography affect outcomes in PCL. A study of hospitalized PCL patients in the United States found no statistically significant differences in hospitalization rates based on race or ethnicity, nor based on neighborhood income, hospital region, or insurance status.²² That said, the study was limited to hospitalization patterns and does not capture the full picture of treatment access, clinical trial enrollment, or long-term outcomes. The rarity of the disease makes it difficult to study disparities with statistical power, and it is plausible that differences in access to specialized centers, newer drugs, or transplant programs exist but are hard to detect in small datasets. Patients diagnosed at high-volume academic centers with experience treating PCL tend to receive more aggressive, multiagent regimens and have better access to transplant and clinical trials, which likely translates into better survival regardless of demographic background.